Most men taking ED medication are told the same general advice: take it around half an hour to 1 hour before sexual activity. This is a reasonable baseline, but it doesn't show the complete picture. Randomised controlled trials specifically designed to measure onset, using stopwatches in at-home settings and rigidity monitors in clinics, have produced precise data showing not just when each medicine typically starts working, but how quickly the fastest responders respond, and exactly what slows that down. This guide goes into detail about these findings so you can form accurate expectations about each medication and make informed decisions about which is right for you.
Why Timing Matters
All four ED treatments available at Pharmica (sildenafil, tadalafil, vardenafil, and avanafil) inhibit the PDE5 enzyme, increasing blood flow to the penis in response to sexual stimulation. None produces an erection independently of arousal.
A significant proportion of men abandon their first ED treatment not because it failed pharmacologically, but because they mistimed the dose. Research into PDE5 inhibitor non-response consistently identifies incorrect timing and insufficient sexual stimulation as the leading correctable causes of treatment failure. Understanding the clinical data by treatment gives you a more accurate picture of each medication's effects, and a better chance of getting it right first time.
What "Onset" Means in the Clinical Trials
Before working through the data treatment by treatment, we need to understand how onset is defined in clinical trials.
The gold standard measure in onset trials is time to successful intercourse, assessed by stopwatch from dose administration to the moment an erection adequate for penetration (that led to completed intercourse) was achieved. This is a real-world functional measure, not a laboratory measure of blood drug concentration. A separate line of research used RigiScan® penile rigidity monitors to detect very early increases in tumescence under controlled clinic conditions, sometimes revealing onset even before the stopwatch studies captured it.
Both types of study are referenced below, but the at-home stopwatch trials carry the most practical weight for patients.
Sildenafil: What the Stopwatch Studies Found
Sildenafil's prescribing information recommends a dosing window of 30 to 60 minutes before sexual activity, with effects possible from 30 minutes to 4 hours post-dose. A landmark randomised controlled trial designed specifically to measure minimal time to onset added important precision to this picture.
In a double-blind, placebo-controlled study of 228 men (115 on sildenafil 100mg, 113 on placebo) who were confirmed responders, participants used a stopwatch from dose to erection sufficient for successful intercourse, taken at least 2 hours after eating. The trial found sildenafil was already producing a statistically superior response versus placebo at 14 minutes. By 20 minutes, 51% of sildenafil-treated men had achieved an adequate erection, compared with 30% on placebo. The median time to erection leading to successful intercourse was 36 minutes.
This is meaningfully faster than the packaging suggests. The 60-minute instruction reflects median peak plasma concentration (Tmax: 30 to 120 minutes, median 60 minutes), not time to pharmacodynamic effect, which the trial showed can precede peak concentration substantially. In practice, sildenafil can work within 30 minutes for many men, but peak reliability sits closer to 45 to 60 minutes when taken fasted.
Tadalafil: Earlier Onset Than Most Men Expect
Tadalafil has the longest half-life of any licensed PDE5 inhibitor (approximately 17.5 hours), which underpins its 36-hour coverage window and the daily 5mg option. Its Tmax in pharmacokinetic studies is approximately 2 hours, much longer than sildenafil, which leads many to assume onset is slower. A dedicated at-home RCT challenged this assumption directly.
In a multicentre, randomised, double-blind, placebo-controlled parallel-group study, men with ED attempted intercourse within 30 minutes of dosing with tadalafil 10mg, 20mg, or placebo across four separate occasions, recording outcomes by stopwatch. The key finding: a statistically significant erectogenic response to tadalafil 20mg was measurable from 16 minutes after dosing. Fifty-two percent of men on tadalafil 20mg had at least one successful intercourse attempt within 30 minutes, versus 35% on placebo.
Tadalafil therefore has a meaningfully earlier pharmacodynamic onset than its Tmax would suggest. This reflects the non-linear nature of PDE5 inhibition. Even at sub-peak concentrations, there is sufficient enzyme inhibition to produce a functional response in many men. In practice, on-demand tadalafil (10mg or 20mg) can be taken 30 minutes before sexual activity. And if an attempt within the first hour is unsuccessful, the medication remains active far longer than sildenafil.
Vardenafil (Levitra): The Fastest First-Generation Option
Vardenafil and Levitra share a Tmax of approximately 45 to 60 minutes with sildenafil, but the at-home stopwatch data suggests pharmacodynamic onset may, in a minority of men, be marginally earlier.
A prospective, randomised, double-blind, placebo-controlled at-home study of 732 men (237 on vardenafil 10mg, 248 on vardenafil 20mg, 247 on placebo) recorded time from dosing to erection adequate for penetration using a stopwatch across the first four doses. A statistically superior response was observed versus placebo as early as 10 to 11 minutes after dosing in responders. In retrospective analysis, 75 to 77% of intercourse attempts initiated within 15 minutes of dosing were successful in vardenafil-treated men, compared with 45 to 47% in the placebo group.
A synthesis across all three first-generation agents published alongside the tadalafil onset data puts the earliest clinical response times in context: approximately 35% of sildenafil-treated men respond from 14 minutes, 32% of tadalafil-treated men from 16 minutes, and 23% of vardenafil-treated men from 11 minutes. The differences between drugs at the earliest time points are modest. The more practically significant difference between vardenafil and sildenafil for most patients is not onset speed, but food sensitivity.
Avanafil (Spedra): The Timing Case for a Second-Generation Drug
Spedra (avanafil) was specifically engineered for faster onset than the first-generation PDE5 inhibitors. Its Tmax is approximately 35 minutes and its half-life is under 1.5 hours, a pharmacokinetic profile that reflects a deliberate design choice prioritising early effect over duration.
A randomised, double-blind, placebo-controlled trial measured successful intercourse within approximately 15 minutes of dosing with avanafil 100mg, 200mg, or placebo across an 8-week treatment period in 440 men with ED, using a stopwatch as the primary outcome measure. Significantly greater proportions of successful attempts within 15 minutes were observed for both doses of avanafil versus placebo. The treatment difference was statistically significant from 10 minutes post-dose in the 200mg group and from 12 minutes in the 100mg group.
A separate head-to-head RCT comparing avanafil directly with sildenafil confirmed avanafil's superiority in the proportion of doses leading to erection within 15 minutes, establishing faster onset as a pharmacologically distinctive feature rather than a marketing claim.
Avanafil is therefore the clinically appropriate option when the 30 to 60 minute planning window associated with first-generation drugs is genuinely impractical. It can be taken 15 to 30 minutes before sexual activity and, importantly, was studied under food and moderate alcohol conditions without the same absorption concerns that apply to sildenafil.
How Food Changes the Timing Equation
Food interaction is where the timing differences between treatments become most practically significant, and where the clinical data is most specific.
Sildenafil is the most food-sensitive of the four. A high-fat meal delays sildenafil's Tmax by approximately one hour and reduces peak plasma concentration (Cmax) by 29%. A dedicated randomised trial examining food and dose timing confirmed that sildenafil taken at the time of a high-fat meal had a clinically meaningful reduction in early onset reliability compared with fasted administration. Food is the single most controllable variable affecting how quickly sildenafil works. On an empty stomach, onset is predictable. After a large meal, it is not.
Vardenafil shows a similar food sensitivity to sildenafil. High-fat meals can substantially delay onset for standard vardenafil tablets, primarily through delayed gastric emptying and pH-dependent solubility effects. The same fasted or light meal guidance applies.
Tadalafil is not meaningfully affected by food, a well-established distinction and a practical advantage for men who find timing around meals difficult.
Avanafil was studied in clinical trials administered after food and moderate alcohol, with efficacy maintained. It does not carry the same food-timing caution as sildenafil or vardenafil.
What This Means for Choosing a Treatment
The clinical trial data on timing points toward a few practical conclusions.
If spontaneity and minimal planning are the priority, avanafil (Spedra) has the most clinical evidence behind its 15-minute onset claim. It outperforms first-generation treatments on onset speed in direct comparison, can be taken around food, and suits men who prefer a shorter pharmacological window (around 5 hours).
If planning ahead is manageable and duration matters more, tadalafil offers 36-hour coverage with onset from 30 minutes in most men. The daily 5mg formulation eliminates timing decisions entirely for men who want a consistent background level of the drug.
If consistency at the lowest cost is the goal, generic sildenafil is the most extensively studied treatment and offers genuine early onset, but managing food intake around the dose is a non-trivial factor that has a direct, measurable impact on how quickly it works.
Vardenafil (Levitra) occupies similar clinical territory to sildenafil in terms of timing, with clinical guidance noting particular efficacy in men with diabetes where other PDE5 inhibitors have been less reliable.
If you are unsure which treatment suits your circumstances, the ED Trial Pack lets you compare sildenafil and tadalafil before committing to a single treatment. The full range of ED treatments available at Pharmica includes all four active ingredients discussed in this article.
This article is intended for informational purposes only and does not constitute medical advice. Always read the patient information leaflet supplied with your medication and consult a healthcare professional with any specific concerns about dosing or drug interactions.
References